JP2003516957A - 特に粘膜塗布用の溶液又は懸濁状の有効成分を入れるためのゲル形状組成物及び製造方法 - Google Patents
特に粘膜塗布用の溶液又は懸濁状の有効成分を入れるためのゲル形状組成物及び製造方法Info
- Publication number
- JP2003516957A JP2003516957A JP2001544659A JP2001544659A JP2003516957A JP 2003516957 A JP2003516957 A JP 2003516957A JP 2001544659 A JP2001544659 A JP 2001544659A JP 2001544659 A JP2001544659 A JP 2001544659A JP 2003516957 A JP2003516957 A JP 2003516957A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- active ingredient
- product
- composition
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 239000004480 active ingredient Substances 0.000 title claims abstract description 22
- 210000004400 mucous membrane Anatomy 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000000725 suspension Substances 0.000 title 1
- 239000000227 bioadhesive Substances 0.000 claims abstract description 9
- 210000004877 mucosa Anatomy 0.000 claims abstract description 9
- 239000003349 gelling agent Substances 0.000 claims abstract description 7
- 229920001983 poloxamer Polymers 0.000 claims description 21
- 229920002125 Sokalan® Polymers 0.000 claims description 13
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 11
- 229960000502 poloxamer Drugs 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000003433 contraceptive agent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical group C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002688 persistence Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 230000035587 bioadhesion Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001248 thermal gelation Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000013008 thixotropic agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/15763 | 1999-12-14 | ||
| FR9915763A FR2802097B1 (fr) | 1999-12-14 | 1999-12-14 | Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication |
| PCT/FR2000/003533 WO2001043720A1 (fr) | 1999-12-14 | 2000-12-14 | Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516957A true JP2003516957A (ja) | 2003-05-20 |
| JP2003516957A5 JP2003516957A5 (https=) | 2008-01-31 |
Family
ID=9553244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001544659A Pending JP2003516957A (ja) | 1999-12-14 | 2000-12-14 | 特に粘膜塗布用の溶液又は懸濁状の有効成分を入れるためのゲル形状組成物及び製造方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030091642A1 (https=) |
| EP (1) | EP1237537B1 (https=) |
| JP (1) | JP2003516957A (https=) |
| AT (1) | ATE336987T1 (https=) |
| AU (1) | AU2525601A (https=) |
| CA (1) | CA2394416A1 (https=) |
| CY (1) | CY1106249T1 (https=) |
| DE (1) | DE60030319T2 (https=) |
| DK (1) | DK1237537T3 (https=) |
| ES (1) | ES2270895T3 (https=) |
| FR (1) | FR2802097B1 (https=) |
| PT (1) | PT1237537E (https=) |
| WO (1) | WO2001043720A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7210833B2 (ja) | 2012-07-31 | 2023-01-24 | エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ | Ｃｏｘ阻害薬を含有する経皮製剤 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20031640A1 (it) | 2003-08-08 | 2005-02-09 | Mipharm S P A | Base per gel bioadesivi. |
| US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
| AU2004274000B2 (en) * | 2003-09-19 | 2009-07-30 | Drugtech Corporation | Pharmaceutical delivery system |
| US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
| CA2605341A1 (en) * | 2005-05-09 | 2006-11-16 | Drugtech Corporation | Modified-release pharmaceutical compositions |
| CN101374501A (zh) * | 2006-01-05 | 2009-02-25 | 药物技术公司 | 组合物及其使用方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05262670A (ja) * | 1991-12-19 | 1993-10-12 | Lek Tovarna Farmacevtskih | 熱可逆性ゲル、液状ガレン製剤及びその製造方法 |
| JPH07309763A (ja) * | 1993-12-31 | 1995-11-28 | Lab Cusi Sa | クロベタゾンおよびトブラマイシンを含有する医薬製剤とその応用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252318A (en) * | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| JP2533723B2 (ja) * | 1992-12-28 | 1996-09-11 | 東興薬品工業株式会社 | 速乾性ゲルタイプ手指消毒剤 |
| US5902110A (en) * | 1995-12-18 | 1999-05-11 | The Block Drug Company | Bone regeneration |
| US5869601A (en) * | 1996-04-05 | 1999-02-09 | S. C. Johnson & Son, Inc. | Method of stabilizing the viscosity of a thickened composition |
| EP1011609A4 (en) * | 1997-05-09 | 2000-08-16 | Medlogic Global Corp | COMPOSITIONS FOR COSMETIC APPLICATIONS |
| US7064114B2 (en) * | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
-
1999
- 1999-12-14 FR FR9915763A patent/FR2802097B1/fr not_active Expired - Fee Related
-
2000
- 2000-12-14 ES ES00988913T patent/ES2270895T3/es not_active Expired - Lifetime
- 2000-12-14 WO PCT/FR2000/003533 patent/WO2001043720A1/fr not_active Ceased
- 2000-12-14 DE DE60030319T patent/DE60030319T2/de not_active Expired - Lifetime
- 2000-12-14 DK DK00988913T patent/DK1237537T3/da active
- 2000-12-14 AT AT00988913T patent/ATE336987T1/de active
- 2000-12-14 JP JP2001544659A patent/JP2003516957A/ja active Pending
- 2000-12-14 EP EP00988913A patent/EP1237537B1/fr not_active Expired - Lifetime
- 2000-12-14 CA CA002394416A patent/CA2394416A1/fr not_active Abandoned
- 2000-12-14 US US10/149,695 patent/US20030091642A1/en not_active Abandoned
- 2000-12-14 PT PT00988913T patent/PT1237537E/pt unknown
- 2000-12-14 AU AU25256/01A patent/AU2525601A/en not_active Abandoned
-
2006
- 2006-11-16 CY CY20061101679T patent/CY1106249T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05262670A (ja) * | 1991-12-19 | 1993-10-12 | Lek Tovarna Farmacevtskih | 熱可逆性ゲル、液状ガレン製剤及びその製造方法 |
| JPH07309763A (ja) * | 1993-12-31 | 1995-11-28 | Lab Cusi Sa | クロベタゾンおよびトブラマイシンを含有する医薬製剤とその応用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7210833B2 (ja) | 2012-07-31 | 2023-01-24 | エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ | Ｃｏｘ阻害薬を含有する経皮製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2270895T3 (es) | 2007-04-16 |
| CA2394416A1 (fr) | 2001-06-21 |
| PT1237537E (pt) | 2007-01-31 |
| DE60030319T2 (de) | 2007-08-30 |
| EP1237537B1 (fr) | 2006-08-23 |
| FR2802097B1 (fr) | 2002-12-13 |
| ATE336987T1 (de) | 2006-09-15 |
| FR2802097A1 (fr) | 2001-06-15 |
| DK1237537T3 (da) | 2006-12-27 |
| AU2525601A (en) | 2001-06-25 |
| EP1237537A1 (fr) | 2002-09-11 |
| US20030091642A1 (en) | 2003-05-15 |
| WO2001043720A1 (fr) | 2001-06-21 |
| CY1106249T1 (el) | 2011-06-08 |
| DE60030319D1 (de) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2308045T3 (es) | Composiciones fungicidas, lubricantes de calentamiento y no irritantes en la forma de un gel. | |
| JP6473103B2 (ja) | 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法 | |
| US4883660A (en) | Gel bases for pharmaceutical compositions | |
| US6824762B2 (en) | Nasal spray compositions | |
| AU2018220020C1 (en) | A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site. | |
| EP0101178B2 (en) | Topical anti-inflammatory compositions | |
| US20120308648A1 (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| JP2002514220A (ja) | 熱傷処置および感染防止のための局部スプレー | |
| JP2001508038A (ja) | 粘膜表面および身体組織に付与可能な薬学的ゲル調製物 | |
| JP3545162B2 (ja) | 口腔用組成物 | |
| KR20050025166A (ko) | 가온성 및 무자극성 윤활제 항진균성 겔 조성물 | |
| WO2001043735A1 (en) | Nitroglycerin ointment for treatment of pain associated with anal disease | |
| JPH10503194A (ja) | 多くの異なる活性成分を含有する医薬組成物、主として腟座薬 | |
| JP2003516957A (ja) | 特に粘膜塗布用の溶液又は懸濁状の有効成分を入れるためのゲル形状組成物及び製造方法 | |
| JP4575632B2 (ja) | 片頭痛緩和用薬剤 | |
| JPWO2001043736A1 (ja) | 片頭痛緩和用薬剤 | |
| JP2003055193A (ja) | 清涼化剤含有ゲル状外用剤 | |
| JP3157082B2 (ja) | 医療用パック型製剤用基剤および医療用パック型製剤 | |
| JPS6251626A (ja) | 外用ゲル組成物 | |
| Kumar | AN OVERVIEW OF EXCIPIENTS USED IN SEMISOLID PREPARATION | |
| WO2019008472A1 (en) | PHARMACEUTICAL COMPOSITIONS OF LIGNOCAINE HCL | |
| CN107638384A (zh) | 经皮递送生理活性物质的水性体系及其技术 | |
| JPS6044344B2 (ja) | 外用アルコ−ルゲル組成物 | |
| HK1132453A (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071203 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100423 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110428 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110511 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110729 |